Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [07/01/2025 16:11 PDT] Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), Up By 100% ($3.85) After BUYINS.NET SqueezeTrigger Report Released on Monday, June 23rd 2025 at a Price of $3.848.
• [07/01/2025 14:55 PDT] Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), Up By 100% ($3.8) After BUYINS.NET SqueezeTrigger Report Released on Monday, June 30th 2025 at a Price of $3.8.
• [06/30/2025 12:04 PDT] SHPH SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [06/23/2025 08:16 PDT] SHPH SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [06/16/2025 07:10 PDT] SHPH Expected to Trade Down After Bearish Patterns Develop
• [06/10/2025 10:30 PDT] Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), Up By 100% ($0.17) From $0.17 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/06/2025 07:16 PDT] SHPH Expected to Trade Up After Bullish Patterns Develop
• [05/09/2025 21:21 PDT] Market Maker Surveillance Report. SHPH, Highest Net Sell Volume and Negative Price Friction For Friday, May 9th 2025